Replies to post #80972 on Biotech Values

[ThomasS]

IDIX: Both items from today:
Idenix Pharma Phase 1b trial has been completed, says Leerink
Leerink believes Idenix's Phase 1b trial for IDX-184 has been completed, despite early challenges in patient accrual. Leerink sees a "good chance" the data is positive and believes it could be announced in conjunction with the company's earnings on Monday. The firm keeps an Outperform rating on the stock.

Idenix Pharma presents attractive risk/reward opportunity, says Thomas Weisel
Thomas Weisel thinks the release of Phase Ib data for Idenix's IDX184 creates an attractive risk/reward opportunity for investors. The firm believes expectations for efficacy data are minimal, but it thinks recent data suggests that IDX184 has better potential to show efficacy than historical results would indicate. The firm maintains an Overweight rating.